Gemma Biotherapeutics ("GEMMABio"), a clinical‑stage, global, genetic medicines company, today announced the presentation of preclinical data supporting candidate declaration for GB703, a novel, ...
Regenxbio is pitching at FDA approval next year for its Duchenne muscular dystrophy (DMD) gene therapy RGX-202, after ...
A cell therapy preserves muscle structure and function in laboratory mice with a type of disease similar to Duchenne muscular dystrophy, according to new research from the Smidt Heart Institute at ...
A research team led by scientists at Cincinnati Children’s Hospital has uncovered a new potential approach to preventing the muscle-wasting symptoms of muscular dystrophy (MD), a family of genetic ...
The muscular dystrophies are characterized by progressive weakness and wasting of striated muscle and are caused by inherited or de novo gene mutation of sarcolemma-associated proteins or nuclear ...
Stem-cell injections worked remarkably well at easing symptoms of muscular dystrophy in a group of golden retrievers, a result that experts call a significant step toward treating people. "It's a ...
Please provide your email address to receive an email when new articles are posted on . New therapies for muscular dystrophy must go beyond traditional corticosteroid administration. Treatments that ...
NEW YORK -- Stem-cell injections worked remarkably well at easing symptoms of muscular dystrophy in a group of golden retrievers, a result that experts call a significant step toward treating people. ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results